Healthcare AI NYSE: HIMS

Hims & Hers Health (HIMS)

AI-powered telehealth at consumer scale.

— loading… 15-min delay · Not financial advice

✓ Reviewed by Get AI Decoded Editorial Team Updated April 2026

The AI Angle

Hims & Hers operates a direct-to-consumer telehealth platform that uses AI to match patients with personalized treatment plans across categories like weight loss (GLP-1), mental health, sexual health, and dermatology. The company's AI layer analyzes patient history, symptom data, and treatment responses to recommend and adjust prescriptions — enabling a high-volume, low-cost clinical model that legacy healthcare can't match.

The GLP-1 weight loss category (compounded semaglutide) drove explosive growth in 2025, pushing full-year revenue to $2.35 billion — up 57% year-over-year. Management guided 2026 revenue to $2.7–2.9 billion, though growth is expected to slow to 15%+ as GLP-1 compounding regulations tighten.

Key Numbers

$2.35B

FY2025 Revenue

+57% YoY growth

$617.8M

Q4 2025 Revenue

+28% YoY

$2.7–2.9B

2026 Revenue Guidance

+15%+ growth guided

~$128M

FY2025 Net Income

Profitable, nearly flat YoY

2/5

AI Exposure Score

Partial AI exposure.

⚡⚡⚡⚡⚡

⚡ About AI Exposure Score: Reflects how central AI is to this company's current revenue and growth strategy. 5 = AI is the core business. 1 = AI is a minor angle. Editorial assessment — not a buy/sell signal.

Get HIMS coverage in your inbox

We cover HIMS and 24 other AI stocks every morning. Free daily newsletter.

Upcoming Catalysts

Novo Nordisk partnership to expand telehealth access to FDA-approved GLP-1 drugs (Mar 27, 2026)
AI-driven platform expansion into new treatment categories beyond GLP-1
International market entry (EU, UK, other English-speaking markets)
GLP-1 regulatory clarity: FDA compounding rules set to finalize in 2026

Key Risks

FDA GLP-1 compounding ban could reduce semaglutide revenue significantly
SEC investigation into GLP-1 marketing and claims disclosures ongoing
Heavy reliance on paid digital marketing for subscriber acquisition
Ozempic/Wegovy brand competition as supply normalizes and pricing drops

Sources: Xtalks (Mar 27, 2026), Pharmacy Times (Mar 26, 2026), Reuters (Mar 2, 2026)

⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.